Anticonvulsants Market 2025 – Market Size & Segments Analysis, Industry Trends, Manufacturers Analysis, Opportunities and Forecast 2034

Page: 215 | Report Code: LS25012201 | Research Suite: Report (PDF) & Market Data (Excel)

NOTE: Due to exhaustive nature of content, full ToC can't be uploaded. Please request Sample Pages to receive full table of content. 

The global anticonvulsants market was valued at 7.1 billion in 2023, and a CAGR of 4.9% is expected during the forecast period. The increasing number of people suffering from epilepsy disease is a significant growth driver in the market. An increasing number of migraine patients and neuropathy patients are driving growth in the market. Increasing availability of third-generation drugs to deal with epilepsy and other brain-related diseases is driving growth in the market significantly.

An increasing number of drug approvals by regulatory authorities are driving growth in the market significantly. Increasing awareness about epilepsy treatments is driving the demand in the market significantly. Increasing demand for the medicines that are FDA approved and are used to treat minor seizures, like Gabapentin, is driving growth in the market significantly.


 Growth Drivers

An increasing number of neurodegenerative disorder patients and rising prevalence of chronic diseases are driving growth in the market. The rising number of stroke patients and patients suffering from brain hemorrhage is driving growth in the market. The increasing number of product recalls by regulatory authorities is also driving growth in the market significantly.

Rising healthcare expenditure all over the world is driving growth significantly in the market. An increasing number of seizure patients are demanding the medicines, like Gabapentin, and are significantly contributing to market growth. Rising awareness about chronic diseases and diagnosis rates, along with the advancements in drug development, are driving growth in the market. Drugs like Gabapentin alter the electrical activity inside the brain, and it helps prevent or reduce the frequency and severity of the seizures.

Increasing demand for medicines like levetiracetam, carbamazepine, and others is dependent on the disease type, the patient’s overall health, and common side effects of medicines. According to WHO, more than 50 million people are suffering from epilepsy at some stage of life. Epilepsy, which is the result of concurrent seizures, is the main cause behind the significant growth.

Segmentation

By Route of Administration

·         Enteral

·         Parenteral

By Drug Class

·         Barbiturates

·         Benzodiazepines

·         Aromatic allylic alcohol

·         Carboxamides

·         Triazine

·         Fatty Acid Derivative

·         GABA Analogs

·         Valproylamides

·         Others

By Indication

·         Epilepsy

·         Neuropathic Pain

·         Anxiety

·         Bipolar Disorders

·         Others

By Distribution Channel

·         Online Pharmacies

·         Retail Pharmacies

·         Hospital Pharmacies

Regional Outlook

·         Asia Pacific

·         North America

·         Latin America

·         Middle East and Africa

·         Europe

The Anticonvulsants Market by Distribution Channel Segmentation

On the basis of the distribution channel, the anticonvulsants market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies. Increasing preference of people for hospital pharmacies over retail and online pharmacies is the reason behind the significant growth in the market. An increasing number of patients with epilepsy, bipolar disorders, and anxiety are driving growth in the market.

Hospital pharmacies are the leading segment because of hospitals’ advanced infrastructure and adequate health facilities significantly. This is responsible for hospital pharmacies eventually leading the market. Retail pharmacies are the second most leading segment because of the easy availability of drugs in these stores.


The Anticonvulsants Market by Indication Segmentation

On the basis of the indication, the antiepileptic market is segmented into epilepsy, neuropathic pain, anxiety, bipolar disorders, and others. Epilepsy is the leading segment due to recurrent seizures, the growing prevalence of epilepsy, and improved diagnostic capabilities are the driving factors behind the market growth. Second-generation anti-epilepsy drugs are the most common and leading segment, and third-generation anti-epilepsy drugs are expected to dominate the market during the forecast period significantly.

Anxiety is the most common disease in today’s world due to lifestyle imbalance. The anti-anxiety drug market includes selective serotonin reuptake inhibitors (SSRIs), benzodiazepines, serotonin-norepinephrine reuptake inhibitors (SNRIs), and beta blockers. Increasing demand for anti-epilepsy and anxiety drugs has driven the growth in the market significantly.

Increase in product approvals for epileptic disorders to drive market growth significantly. Similarly, the online pharmacies segment is expected to grow with a significant CAGR over the study period. This is due to the rising preference for teleconsultation and online pharmacy facilities in developed and emerging nations. Increasing number of epilepsy, and anxiety patients are driving growth in the market.

Regional Outlook

On the basis of the regions, the anticonvulsants market is segmented into 5 regions: Asia Pacific, North America, Latin America, the Middle East and Africa, and Europe. Due to the advanced health care facilities, the increasing number of geriatric people is driving growth in the market significantly. Due to growth in the healthcare facilities and the increasing number of geriatric people, the reason behind the market witnessing significant growth in emerging economies like China, India, Japan, and South Korea is. Still due to the presence of major key players in the North American region, the market is witnessing significant growth during the forecast period.

According to an article published by the Centers for Disease Control and Prevention, almost 3 million US adults have epilepsy issues, and according to WHO, more than 50 million people all over the world are suffering from epilepsy. An increasing number of geriatric people and rising healthcare expenditure are the key factors behind the growth in the European market significantly.

Countries like Germany, France, England, and Russia are witnessing significant growth during the forecast period due to rising healthcare awareness and increasing awareness about the early diagnosis and detection of the diseases. Rising government initiatives supporting epilepsy awareness and expanding use in treating nonepileptic conditions are the key reasons behind the significant growth in the market. Hectic lifestyles and rising epilepsy cases all over the world are driving growth in the market. Europe is home to the key players in the market. Denmark, Norway, Egypt, Italy, France, Germany, the Netherlands, and Poland are witnessing significant growth in the market.


Egypt in the African region is witnessing moderate growth, and the United Arab Emirates and Saudi Arabia are the countries witnessing growth due to rising healthcare expenditure and an increasing number of epilepsy cases.

 Key Players

·         Novartis AG

·         Johnson and Johnson

·         Teva Pharmaceuticals Ltd.

·         Pfizer Inc.

·         Dr. Reddy’s Laboratories Ltd.

·         Jazz Pharmaceuticals

·         Bausch Health Companies Inc.

·         Sumitomo Pharma Company

·         Zogenix

·        Sun Pharm

·         Eisai Co. Ltd

·         SK Life Science

·         Other Player

Buy Report

  • $1990
  • $2990